* Estimated timing for top-line results for Phase II study
with Bekinda for IBS-D are anticipated in mid-2017
Source text for Eikon:
Further company coverage:
The post BRIEF-Redhill Biopharma provides 2016 semi-annual research and development update appeared first on NASDAQ.